CLLS
NASDAQ
$2.60
Cellectis (CLLS)
Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors to attack and eradicate cancer cells. The company is headquartered in Paris, France.
Sector:
Healthcare
Industry:
Biotechnology
Strong Buy
Target: $7.60 (+192.31%)
Market Cap
$282M
Free Cash Flow Yield
-14.21%
Beta (5Y)
0.94
Price Chart
Valuation
Market Cap$282M
P/S3.85
P/B4.87
Profitability
Total Revenue (TTM)$68M
Gross Profit (TTM)$75M
EBITDA-$51M
Profit Margin-89.5%
Operating Margin-333.4%
EPS-$0.67
Financial Health
Debt-to-Equity181.2%
Free Cash Flow Yield-14.21%
Growth & Risk
EPS 5Y CAGR-24.18%
Revenue 5Y CAGR+6.98%
FCF 5Y CAGR-25.00%
Beta (5Y)0.94
Sharpe Ratio0.72